NEWS
NEWS
Multiple Milner affiliates recognised at Cambridge Independent Science and Technology Awards
We are delighted that several of our affiliated companies were recognised at the 2023 Cambridge Independent Science & Technology Awards last...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
We are delighted to welcome Dr Cathy Tralau-Stewart as the new Executive Director at the Milner Therapeutics Institute. Cathy will work alongside...
Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning...
Milner Institute announces strategic collaboration with NC3Rs
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate...
Milner affiliate STORM Therapeutics initiate phase I clinical trials
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class...
MSD joins Milner Therapeutics Consortium
This month we are excited to announce that MSD has joined the Milner Therapeutics Consortium as our 12th pharma partner. This coincides with the...
Milner pharma partner visit to Barcelona affiliated institutes
A long-term priority for the Milner is to share our experience of working with industry with other academic institutes, with the goal of fostering...
Pathania group receive £1m to investigate children’s brain tumours
We are delighted that Dr Manav Pathania and team, who are based at the Milner Therapeutics Institute, have been awarded ~£1 million from Cancer...
Video showcase of Milner collaborations with CRUK Cambridge Centre
In May 2021, the Milner Institute launched a rapid response data analysis call, led by Dr Rebecca Harris. The call sought collaborative project...
Milner Institute recognized at Vice-Chancellor’s Awards for Research, Impact and Engagement
We were delighted to receive an award at the Vice-Chancellor's Awards for Research, Impact and Engagement last week. Milner Directors Tony...
Head of Entrepreneurship joins Milner team
We are delighted to announce that Alexandra Huener has joined the Milner team as the Head of Entrepreneurship. This exciting new role has been...
Milner welcomes paediatric patients for Patient Research & Science day
The Milner team enjoyed an institute visit with a difference last week, as we welcomed a group of children for Inflammatory Bowel Disease (IBD)...
Milner Institute celebrates success of first hybrid Therapeutics Symposium
Our first ever hybrid Therapeutics Symposium was held at the end of June and we were thrilled to welcome over 350 delegates at West Road Concert...
AI drug target discovery company co-founded by Namshik Han receives £1.4 million pre-seed investment
CardiaTec, a company co-founded by Milner Head of Computational Biology Dr Namshik Han, has secured £1.4 million pre-seed investment to...
Deputy Director Kathryn Chapman receives CEO Today Business Women of the Year Award
The CEO Today Business Women of the Year Awards 2022 edition has been published this week, and we're delighted that Milner Deputy Director Kathryn...
Milner – LifeArc strategic partnership extended for five years
We are thrilled to announce that the Milner collaboration with the medical research charity LifeArc has been expanded into a 5-year strategic...
Milner Institute wins award for innovation at Cambridge Independent Science and Technology Awards
We are honoured to have been announced as highly commended in the Innovation category of the 2022 Cambridge Independent Science & Technology...
Milner Institute announced as finalist in the Cambridge Independent Science and Technology Awards
We are delighted that the Milner Therapeutics Institute has been announced as a finalist for the Award for Innovation in the 2021-2022 Cambridge...
Milner Therapeutics Institute promoted to Affiliated Institute of CRUK Cambridge Centre
We are delighted to announce that, with the renewal of the CRUK Cambridge Centre this year, the Milner will become an Affiliated Institute,...
MTI welcomes George Freeman MP, to learn how Cambridge is leading innovation in life sciences
We were delighted to welcome George Freeman MP, the Parliamentary under Secretary of State in the Department for Business, Energy and Industrial...
Director Tony Kouzarides receives Cyprus Excellence in Science award
The President of Cyprus, Nicos Anastasiades, presented our Director Tony Kouzarides with the prestigious Excellence in Science Award this week, on...
Milner Institute wins OBN Award for Most Impactful Business Support Organisation
This week, Deputy Director Kathryn Chapman and Communications Manager Nikki Mann represented the Milner team at the OBN Awards in Oxford, and we are...
KPBMA bring international partners to Milner affiliate network
We are delighted to share that KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) has joined as an Affiliated Organization of...
Astellas join Milner Therapeutics Consortium
We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global...
Milner Institute announced as finalist for OBN Award
We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful...
Milner collaboration uncovers promising target for new drug development
Research in the Tzelepis lab, in collaboration with scientists from the Wellcome Sanger Institute and Harvard University, has identified a protein...
Milner group use combination of computational biology and machine learning to create comprehensive map of proteins involved in SARS-CoV-2 infection
Namshik Han's group at the Milner Therapeutics Institute, have identified 200 approved drugs predicted to work against COVID-19 – of which only 40...
Connect: Health Tech is launched
We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite and online community platform, as part...
Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in...
Affiliate Companies showcase their work
As we reach the end of what has been the most challenging and difficult year so far, we want to take the time to celebrate the achievements of our...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the...
Start Codon closes new £15 million venture fund
Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed...
OncoInnovation: TGIO 2020 Challenge winner
Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early...
Kostas Tzelepis awarded John Goldman Fellowship
We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and...
Kathryn Lilley awarded EMBO membership
We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been...
Start Codon announces first cohort of companies
Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were...
Eisai join Milner Therapeutics Consortium
We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading...
Milner Institute illuminated blue for the NHS
The Jeffrey Cheah Biomedical Centre illuminated blue tonight, to honour the incredible work of our NHS. Milner Institute Director Professor Tony...
Milner seminars move online
We have been busy adapting plans for the coming months, and are pleased to announce that our Milner seminars are moving online. The first talk is...
Welcome to the Tzelepis Group
We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings...
A look inside the institute
For the past four years, the Milner Therapeutics Institute has been incubating in the Gurdon Institute – home to the research lab of our Director...
Launch of the Milner Therapeutics Institute
This month, we celebrated the launch of the Milner Therapeutics Institute in the Jeffrey Cheah Biomedical Centre. Key academics and consortium...
AstraZeneca-Cancer Research UK Functional Genomics Centre launch
We are excited to be celebrating the launch of the AstraZeneca-Cancer Research UK Functional Genomics Centre today. Based in the Milner Therapeutics...
Welcome to Cambridge Centre for Proteomics
A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute...
First pre-competitive project initiated
A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using...
New University Enterprise Zone announced
The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by...
Welcome to Pathania group
We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a...
